Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Robert F. Kennedy Jr., if confirmed as HHS secretary, could help food-as-medicine startups expand with wider government health plan coverage.

Novo Nordisk's blockbuster drug is now a kidney disease fighter, threatening dialysis giants and reshaping the ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Eli Lilly has been unable to secure an accelerated ... have to wait until it can start negotiating with the Centres for Medicare and Medicaid Services (CMS) on reimbursement, losing ground to ...

Early moves by the president raise questions about what direction his second-term policy on drug costs will take.

Citi raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...

Eli Lilly is a top producer of insulin and antibiotics, and a growing force in weight loss drugs and treatments for Alzheimer’s. The company is also known for drugs to treat diabetes (Trulicity ...

Steep new fines — more than many people make in a month — have made the streets of Ho Chi Minh City and Hanoi less freewheeling than they used to be. By Damien Cave When Colombia’s ...